Lorenzo Leggio1, William H Zywiak2, Samuel R Fricchione3, Steven M Edwards4, Suzanne M de la Monte5, Robert M Swift6, George A Kenna7. 1. Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland; Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland; Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, Providence. Electronic address: lorenzo.leggio@nih.gov. 2. Decision Sciences Institute, Pacific Institute for Research and Evaluation, Pawtucket; Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, Providence, Rhode Island. 3. Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, Providence. 4. Department of Psychology, University of Nebraska-Lincoln, Lincoln, Nebraska. 5. Departments of Pathology, Neurology, and Neurosurgery, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, Rhode Island. 6. Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, Providence, Rhode Island; Veterans Affairs Medical Center, Providence, Rhode Island. 7. Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, Providence, Rhode Island.
Abstract
BACKGROUND: There is a need to identify novel pharmacologic targets to treat alcoholism. Animal and human studies suggest a role for ghrelin in the neurobiology of alcohol dependence and craving. Here, we were the first to test the hypothesis that intravenous administration of exogenous ghrelin acutely increases alcohol craving. METHODS: This was a double-blind, placebo-controlled human laboratory proof-of-concept study. Nontreatment-seeking, alcohol-dependent, heavy-drinking individuals were randomized to receive intravenous ghrelin 1 mcg/kg, 3 mcg/kg or 0 mcg/kg (placebo), followed by a cue-reactivity procedure, during which participants were exposed to neutral (juice) and alcohol cues. The primary outcome variable was the increase in alcohol craving (also called urge) for alcohol, assessed by the Alcohol Visual Analogue Scale. RESULTS:Out of 103 screenings, 45 individuals received the study drug. Repeated measures of analysis of covariance revealed a group effect across ghrelin doses in increasing alcohol craving (p < .05). A dose-specific examination revealed a significant effect of ghrelin 3 mcg/kg versus placebo in increasing alcohol craving (p < .05) with a large effect size (d = .94). By contrast, no significant ghrelin effect was found in increasing either urge to drink juice or food craving (p = ns). No significant differences in side effects were found (p = ns). CONCLUSIONS: Intravenous administration of exogenous ghrelin increased alcohol craving in alcohol-dependent heavy-drinking individuals. Although the small sample requires confirmatory studies, these findings provide preliminary evidence that ghrelin may play a role in the neurobiology of alcohol craving, thus demonstrating a novel pharmacologic target for treatment. Published by Elsevier Inc.
RCT Entities:
BACKGROUND: There is a need to identify novel pharmacologic targets to treat alcoholism. Animal and human studies suggest a role for ghrelin in the neurobiology of alcohol dependence and craving. Here, we were the first to test the hypothesis that intravenous administration of exogenous ghrelin acutely increases alcohol craving. METHODS: This was a double-blind, placebo-controlled human laboratory proof-of-concept study. Nontreatment-seeking, alcohol-dependent, heavy-drinking individuals were randomized to receive intravenous ghrelin 1 mcg/kg, 3 mcg/kg or 0 mcg/kg (placebo), followed by a cue-reactivity procedure, during which participants were exposed to neutral (juice) and alcohol cues. The primary outcome variable was the increase in alcohol craving (also called urge) for alcohol, assessed by the Alcohol Visual Analogue Scale. RESULTS: Out of 103 screenings, 45 individuals received the study drug. Repeated measures of analysis of covariance revealed a group effect across ghrelin doses in increasing alcohol craving (p < .05). A dose-specific examination revealed a significant effect of ghrelin 3 mcg/kg versus placebo in increasing alcohol craving (p < .05) with a large effect size (d = .94). By contrast, no significant ghrelin effect was found in increasing either urge to drink juice or food craving (p = ns). No significant differences in side effects were found (p = ns). CONCLUSIONS: Intravenous administration of exogenous ghrelin increased alcohol craving in alcohol-dependent heavy-drinking individuals. Although the small sample requires confirmatory studies, these findings provide preliminary evidence that ghrelin may play a role in the neurobiology of alcohol craving, thus demonstrating a novel pharmacologic target for treatment. Published by Elsevier Inc.
Authors: Jeffrey M Zigman; Juli E Jones; Charlotte E Lee; Clifford B Saper; Joel K Elmquist Journal: J Comp Neurol Date: 2006-01-20 Impact factor: 3.215
Authors: Giovanni Addolorato; Esmeralda Capristo; Lorenzo Leggio; Anna Ferrulli; Ludovico Abenavoli; Noemi Malandrino; Sara Farnetti; Marco Domenicali; Cristina D'Angelo; Luisa Vonghia; Antonio Mirijello; Silvia Cardone; Giovanni Gasbarrini Journal: Alcohol Clin Exp Res Date: 2006-11 Impact factor: 3.455
Authors: Elisabet Jerlhag; Emil Egecioglu; Suzanne L Dickson; Annika Douhan; Lennart Svensson; Jörgen A Engel Journal: Addict Biol Date: 2007-03 Impact factor: 4.280
Authors: Filippo Cremonini; Michael Camilleri; Maria Vazquez Roque; Sanna McKinzie; Duane Burton; Kari Baxter; Alan R Zinsmeister Journal: Gastroenterology Date: 2006-09-20 Impact factor: 22.682
Authors: Thomas Kraus; Anja Schanze; Michael Gröschl; Kristina Bayerlein; Thomas Hillemacher; Udo Reulbach; Johannes Kornhuber; Stefan Bleich Journal: Alcohol Clin Exp Res Date: 2005-12 Impact factor: 3.455
Authors: Mary R Lee; Mehdi Farokhnia; Enoch Cobbina; Anitha Saravanakumar; Xiaobai Li; Jillian T Battista; Lisa A Farinelli; Fatemeh Akhlaghi; Lorenzo Leggio Journal: Neuropharmacology Date: 2019-09-23 Impact factor: 5.250
Authors: Kati L Healey; Justine D Landin; Kira Dubester; Sandra Kibble; Kristin Marquardt; Julianna N Brutman; Jon F Davis; H Scott Swartzwelder; L Judson Chandler Journal: Alcohol Date: 2020-01-07 Impact factor: 2.405
Authors: Grzegorz Godlewski; Resat Cinar; Nathan J Coffey; Jie Liu; Tony Jourdan; Bani Mukhopadhyay; Lee Chedester; Ziyi Liu; Douglas Osei-Hyiaman; Malliga R Iyer; Joshua K Park; Roy G Smith; Hiroshi Iwakura; George Kunos Journal: Cell Metab Date: 2019-05-16 Impact factor: 27.287